CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 2, 2016
Result type: Reports
Project Number: SR0493-000
Product Line: Reimbursement Review

Generic Name: Levofloxacin

Brand Name: Quinsair

Manufacturer: Raptor Pharmaceuticals Inc.

Indications: Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 21, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions